12 results on '"Sriuranpong, V."'
Search Results
2. 10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% — 3-year update
3. P42.02 Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited Country
4. FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
5. OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
6. P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
7. P018 Afatinib Named Patient Use Program in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers
8. P2.01-104 Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC is Not Correlated with TIL but has a Potential of Prognostic Value
9. P3.01-042 Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study
10. OA 05.02 Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
11. PCN18 ECONOMIC IMPLICATIONS OF THE FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THAILAND: A COST EFFECTIVENESS ANALYSIS
12. PCN15 COST ANALYSIS BETWEEN TYROSINE KINASE INHIBITOR VERSUS DOCETAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.